Cargando…

Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes

Chronic graft-versus-host disease (cGVHD) is a major limitation to the long-term success of allogeneic hematopoietic cell transplantation (HCT). Our prior study of acute GVHD (aGVHD) defined distinct treatment-response groups based on the response to first-line corticosteroids: steroid-sensitive (SS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herzog, Shannon, Weisdorf, Daniel J., Shanley, Ryan, Rayes, Ahmad, Holtan, Shernan G., Young, Jo-Anne, MacMillan, Margaret L., El Jurdi, Najla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Transplantation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365934/ https://www.ncbi.nlm.nih.gov/pubmed/37036949 http://dx.doi.org/10.1182/bloodadvances.2022009505

Ejemplares similares

High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group
por: El Jurdi, Najla, et al.
Publicado: (2021)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium
por: DeFilipp, Zachariah, et al.
Publicado: (2021)

Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
por: Holtan, Shernan G., et al.
Publicado: (2023)

Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
por: Akahoshi, Yu, et al.
Publicado: (2023)

Allodepleted T‐cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft‐versus‐host disease (GVHD) in the absence of GVHD prophylaxis
por: Roy, Denis Claude, et al.
Publicado: (2019)

Steroid-Refractory Acute GVHD: Predictors and Outcomes
por: Westin, Jason R., et al.
Publicado: (2011)

Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure
por: Stenger, Elizabeth O., et al.
Publicado: (2023)

PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation
por: Al-Homsi, A. Samer, et al.
Publicado: (2023)

Donor bone marrow–derived macrophage MHC II drives neuroinflammation and altered behavior during chronic GVHD in mice
por: Adams, Rachael C., et al.
Publicado: (2022)

Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in GVHD Risk Without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate
por: El Jurdi, Najla, et al.
Publicado: (2023)

Third-party type 2 innate lymphoid cells prevent and treat GI tract GvHD
por: Bruce, Danny W., et al.
Publicado: (2021)

Acute GVHD, BK virus hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults
por: Vasu, Sumithira, et al.
Publicado: (2022)

ICOS immunoPET enables visualization of activated T cells and early diagnosis of murine acute gastrointestinal GvHD
por: Xiao, Zunyu, et al.
Publicado: (2022)

Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation
por: Ueda Oshima, Masumi, et al.
Publicado: (2023)

Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning
por: Iwasaki, Makoto, et al.
Publicado: (2022)

The day 100 score predicts moderate to severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation
por: Metafuni, Elisabetta, et al.
Publicado: (2022)

MicroRNA-31 regulates T-cell metabolism via HIF1α and promotes chronic GVHD pathogenesis in mice
por: Wu, Yongxia, et al.
Publicado: (2022)

A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis
por: Yu, Xiaoliang, et al.
Publicado: (2023)

Mesenchymal stromal cells ameliorate chronic GVHD by boosting thymic regeneration in a CCR9-dependent manner in mice
por: Zhang, Xin, et al.
Publicado: (2023)

Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGVHD
por: He, Fiona, et al.
Publicado: (2016)

Single-cell immune profiling reveals a developmentally distinct CD4(+) GM-CSF(+) T-cell lineage that induces GI tract GVHD
por: Piper, Clint, et al.
Publicado: (2022)

Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
por: Sobash, Philip T., et al.
Publicado: (2020)

Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review
por: Holtan, Shernan G., et al.
Publicado: (2022)

Correction to: Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review
por: Holtan, Shernan G., et al.
Publicado: (2022)

NK cells produce high levels of IL‐10 early after allogeneic stem cell transplantation and suppress development of acute GVHD
por: Chan, Yuen Ling Tracey, et al.
Publicado: (2017)

GVHD Prophylaxis 2020
por: Gooptu, Mahasweta, et al.
Publicado: (2021)

Systematic review and meta-analysis of prospective studies for ECP treatment in patients with steroid-refractory acute GVHD
por: Zhang, Hongming, et al.
Publicado: (2015)

Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD
por: Baek, Dong Won, et al.
Publicado: (2022)

Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
por: Liu, Yin, et al.
Publicado: (2022)

Mesenchymal stem cell as salvage treatment for refractory chronic GVHD
por: Weng, J Y, et al.
Publicado: (2010)

Inflammasome effects in GvHD
por: Koehn, Brent H., et al.
Publicado: (2015)

Targeting Cytokines in GVHD Therapy
por: Kumar, Sandeep, et al.
Publicado: (2017)

Editorial: Interferons and GvHD
por: Kim, Boram, et al.
Publicado: (2022)

Regulatory T Cells in GVHD Therapy
por: Guo, Wen-wen, et al.
Publicado: (2021)

Milestones in acute GVHD pathophysiology
por: Socie, Gerard, et al.
Publicado: (2022)

Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric cases
por: Wernicke, Caroline M, et al.
Publicado: (2011)

2844. Butyrogenic Bacteria After Acute Graft vs. Host Disease Associate with the Development of Steroid Refractory GVHD
por: Golob, Jonathan L, et al.
Publicado: (2019)

Utility of eGVHD App for bedside GVHD assessment in a high-volume BMT center
por: Chhabra, Prashant, et al.
Publicado: (2023)

Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract
por: Biavasco, Francesca, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sif565hcvmbdhh44ddmm6nhnhh